drugset / Trial / NCT02930993
Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label, one center, dose escalation clinical study, to determine the safety and efficacy of infusion of autologous T cells engineered to express chimeric antigen receptor targeting mesothelin in adult patients with mesothelin positive, recurrent or metastatic malignant tumors.
Timeline
- Start
- 2016-08
- Primary completion
- 2018-08
- Completion
- 2019-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-mesothelin CAR-T cells | Cell therapy | 50000 cells/kg | Intravenous |
| Subject | Anti-mesothelin CAR-T cells | Cell therapy | 1e+07 cells/kg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |